Latest News and Press Releases

 - First potentially disease-modifying gene therapy for GM2 gangliosidosis to enter clinical studies- Expect to continue patient identification, screening, and enrollment in Stage 1 of the study...

Company to receive up to $20 million in upfront and milestone payments from non-dilutive transactionTransaction extends cash runway into 2022 NEW YORK, N.Y. and RESEARCH TRIANGLE PARK, N.C., Jan. ...

-  Generally well-tolerated with a favorable safety profile in five patients-  Serum beta-galactosidase enzyme activity increased in all patients at all timepoints between Day 7 and Month 6,...

On-track to report topline results from low-dose cohort by end of 2020 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a...

A pioneering researcher, Dr. Gao has made foundational contributions to the discovery of novel AAV vectors for gene therapyDr. Gao recently served as President of the American Society for Gene and...

Continued progress across pipeline of gene therapy programs, including recent IND clearance for AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseasesCompleted rebranding to Sio Gene Therapies as part of...

Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicinesCompany’s common stock will trade on the NASDAQ...

AXO-AAV-GM2 is the first investigational gene therapy to receive IND clearance in Tay-Sachs and Sandhoff diseasesRepresents Axovant’s second IND clearance for a gene therapy program in the last 12...

Patient-level data in cohort 2 of SUNRISE-PD study demonstrates consistent, clinically meaningful outcomes and evidence of dose responseDelays in manufacturing process expected to postpone the start...

Agenda to feature presentations from leading clinical researchers in Parkinson’s disease and the Michael J. Fox FoundationIndividual patient-level data from Cohort 2 of the Phase 2 SUNRISE-PD study to...